Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis

Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis

Objective: To assess the cost effectiveness of radium-223 dichloride for patients with metastatic castration-resistant prostate cancer (mCRPC) in China.Materials and methods: A Markov model was developed to estimate the long-term health and economic outcomes of radium-223 plus best standard care (BS...

Full description

Bibliographic Details
Main Authors: Xiaohui Zeng, Qiao Liu, Chongqing Tan, Xiaomin Wan, Yunhua Wang, Xiaowei Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Pharmacology
Subjects:
cost effectiveness
radium-223
metastatic castration-resistant prostate cancer
QALY
China
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1003483/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1003483/full

Similar Items